QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
QQQ   337.27 (+1.86%)
AAPL   175.05 (+1.37%)
MSFT   318.52 (+1.44%)
META   246.85 (+1.80%)
GOOGL   122.83 (+1.65%)
AMZN   118.15 (+2.29%)
TSLA   176.89 (+1.74%)
NVDA   316.78 (+4.97%)
NIO   7.82 (-2.62%)
BABA   85.77 (-5.41%)
AMD   107.93 (+4.03%)
T   16.55 (-0.66%)
F   11.64 (+1.22%)
MU   67.57 (+4.08%)
CGC   1.05 (+0.00%)
GE   104.01 (+0.52%)
DIS   93.76 (+1.07%)
AMC   5.07 (-0.59%)
PFE   36.48 (-0.73%)
PYPL   61.27 (-0.31%)
NFLX   371.29 (+9.22%)
NASDAQ:PTCT

PTC Therapeutics (PTCT) Price Target & Analyst Ratings

$58.13
-0.16 (-0.27%)
(As of 05/18/2023 ET)
Compare
Today's Range
$57.16
$59.25
50-Day Range
$44.17
$58.29
52-Week Range
$25.01
$59.25
Volume
865,255 shs
Average Volume
759,211 shs
Market Capitalization
$4.31 billion
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$53.79

PTC Therapeutics Consensus Rating and Price Target (2023)

MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0 to .5 = Strong Sell, .5 to 1 = Sell, 1 to 1.5 = Reduce, 1.5 to 2.5 = Hold, 2.5 to 3.0 = Moderate Buy, 3.0 to 3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.

Consensus Analyst Rating

Hold
Based on 11 Analyst Ratings

Consensus Analyst Price Target

$54.07
-6.99% Downside
High Prediction$70.00
Average Prediction$54.07
Low Prediction$37.00
TypeCurrent
5/18/22 to 5/18/23
1 Month Ago
4/18/22 to 4/18/23
3 Months Ago
2/17/22 to 2/17/23
1 Year Ago
5/18/21 to 5/18/22
Consensus Rating
Hold
Hold
Hold
Hold
Strong Buy
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
0 Strong Buy rating(s)
Buy
5 Buy rating(s)
5 Buy rating(s)
5 Buy rating(s)
4 Buy rating(s)
Hold
5 Hold rating(s)
5 Hold rating(s)
4 Hold rating(s)
4 Hold rating(s)
Sell
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
1 Sell rating(s)
Consensus Price Target$54.07$53.00$54.64$50.75
Predicted Upside-6.99% Downside16.01% Upside23.75% Upside30.24% Upside
Get PTC Therapeutics Upgrade and Downgrade Alerts

Sign-up to receive the latest news and ratings for PTCT and its competitors with MarketBeat's FREE daily newsletter.


PTCT Analyst Ratings By Month

The chart below shows how a company's ratings by analysts have changed over time. Each bar represents the previous year of ratings for that month. Within each bar, the sell ratings are shown in red, the hold ratings are shown in yellow, the buy ratings are shown in green, and the strong buy ratings are shown in dark green.
Skip Chart & View Analyst Rating History

PTCT Price Targets by Month

The chart below shows how a company's share price and consensus price target have changed over time. The dark blue line represents the company's actual price. The lighter blue line represents the stock's consensus price target. The even lighter blue range in the background of the two lines represents the low price target and the high price target for each stock.
Skip Chart and View Analyst Price Target HistorySkip Chart & View Price History Table

PTC Therapeutics Stock vs. The Competition

TypePTC TherapeuticsMedical CompaniesS&P 500
Consensus Rating Score
2.36
2.66
2.48
Consensus RatingHoldBuyHold
Predicted Upside-6.99% Downside1,414.32% Upside164.04% Upside
News Sentiment RatingNeutral News
Neutral News
Neutral News

Historical Target Prices and Ratings

DateBrokerageAnalyst NameActionRatingPrice TargetUpside/Downside on Report DateDetails
5/18/2023VNET Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Reiterated RatingMaintains
5/18/2023Bank of America
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$36.00 ➝ $43.00-26.23%
5/18/2023Citigroup
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$67.00 ➝ $70.00+20.09%
5/18/2023Barclays
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$47.00 ➝ $57.00-2.21%
5/17/2023The Goldman Sachs Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$35.00 ➝ $37.00-36.52%
5/8/2023JPMorgan Chase & Co.
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$57.00 ➝ $64.00+14.65%
4/28/2023Credit Suisse Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$48.00 ➝ $51.00-3.12%
4/18/2023Truist Financial
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$60.00 ➝ $65.00+25.90%
3/22/2023William Blair
Subscribe to MarketBeat All Access for the recommendation accuracy rating
S. Corwin
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingOutperform
3/17/2023SVB Leerink
Subscribe to MarketBeat All Access for the recommendation accuracy rating
J. Schwartz
Subscribe to MarketBeat All Access for the recommendation accuracy rating
Reiterated RatingMarket Perform$48.00-0.21%
3/17/2023SVB Securities
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageMarket Perform$48.00-0.21%
2/23/2023Raymond James
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOutperform$60.00 ➝ $55.00+24.35%
2/22/2023Royal Bank of Canada
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost Target$44.00 ➝ $51.00+17.78%
2/22/2023Cantor Fitzgerald
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower TargetOverweight$68.00 ➝ $66.00+47.58%
2/3/2023Morgan Stanley
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Boost TargetEqual Weight$40.00 ➝ $50.00+5.57%
11/1/2022Cowen
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Lower Target$44.00+16.62%
9/12/2022Jefferies Financial Group
Subscribe to MarketBeat All Access for the recommendation accuracy rating
 Initiated CoverageBuy$62.00+15.59%
(Data available from 5/18/2018 forward. View 10+ years of historical ratings with our analyst ratings screener.)












PTCT Price Target - Frequently Asked Questions

What is PTC Therapeutics's consensus rating and price target?

According to the issued ratings of 11 analysts in the last year, the consensus rating for PTC Therapeutics stock is Hold based on the current 1 sell rating, 5 hold ratings and 5 buy ratings for PTCT. The average twelve-month price prediction for PTC Therapeutics is $54.07 with a high price target of $70.00 and a low price target of $37.00. Learn more on PTCT's analyst rating history.

Do Wall Street analysts like PTC Therapeutics more than its competitors?

Analysts like PTC Therapeutics less than other Medical companies. The consensus rating for PTC Therapeutics is Hold while the average consensus rating for medical companies is Buy. Learn more on how PTCT compares to other companies.

Does PTC Therapeutics's stock price have much upside?

According to analysts, PTC Therapeutics's stock has a predicted upside of 10.81% based on their 12-month price targets.


Stock Ratings Reports and Tools

This page (NASDAQ:PTCT) was last updated on 5/18/2023 by MarketBeat.com Staff

My Account -